摘要
目的比较40mg和10mg阿托伐他汀对ACS合并糖尿病患者糖代谢基因Akt/Glut4的表达是否存在差异。方法 80例ACS合并糖尿病患者随机分为阿托伐他汀40mg和10mg治疗组,于治疗前、治疗后1个月、3个月分别检测空腹血糖(FBG)、血脂等,并应用ELISA双抗体夹心法测定血清中Akt/Glut4表达。结果阿托伐他汀10mg组,于治疗前、治疗后1个月及3个月Akt和Glut4表达水平差异均无统计学意义;40mg治疗组,治疗后3个月与治疗前比较,Akt和Glut4的表达均降低,有显著的统计学差异(P=0.008和P=0.033)。而对于FBG的影响:10mg组及40mg组治疗后3个月较治疗前有升高倾向,但差异无统计学意义(P值分别为0.852和0.650)。结论阿托伐他汀40mg的治疗剂量可以下调糖代谢基因Akt/Glut4在ACS合并糖尿病患者中的表达。40mg阿托伐他汀对空腹血糖的影响不显著。
Objective To compare the effect of different doses of atoreastatin on Akt/Glut4 expressions in ACS patients with Diabetes mellitus. Methods Eighty ACS patients with DM were randomly divided into 2 groups: 10mg/d atorvastatin group (n=40) and 40mg/d atorvastatin group (n=40). All subjects were followed for 3 months. The levels of serum lipid, FBG, ALT, AST, Cr and Akt/Glut4 expressions were measured in all subjects at baseline and month 1, 3 after therapy respectively. Results There were no significant differences in baseline characteristics between the two study groups. In 10rag dose atorvastatin group, there were no significant difference in Akt and glut4 expressions at baseline, 1st and 3rd month after therapy. In 40mg dose atorvastatin group, Akt and glut4 expressions decreased significantly (p=0.008 & p=0.033 respectively) after 3 months therapy. The both 2 groups had an increasing tendency of glucose levels with no statistic significance after 3 months therapy. Conclusion In ACS patients with DM, atorvastatin 40mg dose could negatively adjust the glucose metabolic genes Akt/Glut4 expression. And 10mg and 40mg doses atorvastatin had no significant influence on FBG level.
出处
《中国分子心脏病学杂志》
CAS
2013年第5期659-661,共3页
Molecular Cardiology of China